サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1420990

緑内障治療市場：世界の業界分析、規模、シェア、成長、動向、予測、2023年～2031年

Glaucoma Treatment Market [Product Type: Prostaglandin Analogs (PGAs), Alpha Agonist, Beta Blockers, Cholinergic, Carbonic Anhydrase Inhibitors, Combined Medications] - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日: | 発行: Transparency Market Research | ページ情報: 英文 170 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
緑内障治療市場：世界の業界分析、規模、シェア、成長、動向、予測、2023年～2031年
出版日: 2023年12月12日
発行: Transparency Market Research
ページ情報: 英文 170 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

緑内障治療市場- レポートの範囲

世界の緑内障治療市場に関するTMRのレポートは、過去と現在の成長動向、および2023年から2031年の予測期間中に市場の指標の貴重な洞察を得る機会を研究しています。このレポートは、世界の緑内障治療市場の収益を提供し、2017年から2031年の期間、2023年を基準年、2031年を予測年とみなします。このレポートは、2023年から2031年までの世界の緑内障治療市場の複合年間成長率（CAGR %）も提供します。

このレポートは広範な調査を経て作成されました。1次調査では、調査活動の大部分が行われ、アナリストが主要なオピニオンリーダー、業界リーダー、オピニオンメーカーにインタビューを実施しました。2次調査には、緑内障治療市場を理解するために、主要企業の製品文献、年次報告書、プレスリリース、および関連文書の参照が含まれます。

市場スナップショット
2023年の市場価値 63億米ドル
2031年の市場価値 91億米ドル
CAGR 4.3%

このレポートは、世界の緑内障治療市場の競合情勢を詳しく掘り下げています。世界の緑内障治療市場で活動する主要企業が特定され、それぞれの企業がさまざまな属性の観点からプロファイルされています。会社概要、財務状況、最近の動向、 SWOTは、このレポートで紹介されている世界の緑内障治療市場のプレーヤーの属性です。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場概要

  • イントロダクション
  • 概要
  • 市場力学
  • 世界市場の分析と予測、2023～2031年

第5章 重要な洞察

  • パイプライン分析
  • 主要製品/ブランド分析
  • 主な合併と買収
  • COVID-19のパンデミックが業界に与える影響

第6章 世界市場の分析と予測：製品タイプ別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：製品タイプ別、2023-2031
    • プロスタグランジン類似体（PGA）
    • アルファアゴニスト
    • ベータブロッカー
    • コリン作動薬
    • 炭酸脱水酵素阻害剤
    • 併用薬
  • 市場魅力度分析：製品タイプ別

第7章 世界市場の分析と予測：適応症別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：適応症別、2023-2031
    • 閉塞隅角緑内障（ACG）
    • 開放隅角緑内障（OAG）
    • 続発性緑内障
    • 先天性緑内障
    • その他
  • 市場魅力度分析：適応症別

第8章 世界市場の分析と予測：販売チャネル別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：販売チャネル別、2023-2031
    • 病院薬局
    • 小売薬局
    • オンライン販売
  • 市場魅力度分析：販売チャネル別

第9章 世界市場の分析と予測：地域別

  • 主な調査結果
  • 市場金額予測：地域別、2023-2031
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場魅力度分析：地域別

第10章 北米市場の分析と予測

第11章 欧州市場の分析と予測

第12章 アジア太平洋市場の分析と予測

第13章 ラテンアメリカ市場の分析と予測

第14章 中東およびアフリカ市場の分析と予測

第15章 競合情勢

  • 市場プレーヤー- 競争マトリックス（企業の階層および規模別）
  • 市場シェア分析：企業別（2022年）
  • 企業プロファイル
    • Novartis AG
    • Pfizer, Inc.
    • Merck &Co., Inc.
    • Bausch &Lomb Inc.
    • Allergan Plc
    • Perrigo Plc
    • Teva Pharmaceutical Industries Ltd.
    • Akorn, Inc.
    • Mobius Therapeutics, LLC
図表

List of Tables

  • Table 01: Global Glaucoma Treatment Market Size (US$ Mn) Forecast, by Product Type, 2023-2031
  • Table 02: Global Glaucoma Treatment Market Size (US$ Mn) Forecast, by Indication, 2023-2031
  • Table 03: Global Glaucoma Treatment Market Size (US$ Mn) Forecast, by Sales Channel, 2023-2031
  • Table 04: Global Glaucoma Treatment Market Size (US$ Mn) Forecast, by Region, 2023-2031
  • Table 05: North America Glaucoma Treatment Market Size (US$ Mn) Forecast, by Country, 2023-2031
  • Table 06: North America Glaucoma Treatment Market Size (US$ Mn) Forecast, by Product Type, 2023-2031
  • Table 07: North America Glaucoma Treatment Market Size (US$ Mn) Forecast, by Indication, 2023-2031
  • Table 08: North America Glaucoma Treatment Market Size (US$ Mn) Forecast, by Sales Channel, 2023-2031
  • Table 09: Europe Glaucoma Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023-2031
  • Table 10: Europe Glaucoma Treatment Market Size (US$ Mn) Forecast, by Product Type, 2023-2031
  • Table 11: Europe Glaucoma Treatment Market Size (US$ Mn) Forecast, by Indication, 2023-2031
  • Table 12: Europe Glaucoma Treatment Market Size (US$ Mn) Forecast, by Sales Channel, 2023-2031
  • Table 13: Asia Pacific Glaucoma Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023-2031
  • Table 14: Asia Pacific Glaucoma Treatment Market Size (US$ Mn) Forecast, by Product Type, 2023-2031
  • Table 15: Asia Pacific Glaucoma Treatment Market Size (US$ Mn) Forecast, by Indication, 2023-2031
  • Table 16: Asia Pacific Glaucoma Treatment Market Size (US$ Mn) Forecast, by Sales Channel, 2023-2031
  • Table 17: Latin America Glaucoma Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023-2031
  • Table 18: Latin America Glaucoma Treatment Market Size (US$ Mn) Forecast, by Product Type, 2023-2031
  • Table 19: Latin America Glaucoma Treatment Market Size (US$ Mn) Forecast, by Indication, 2023-2031
  • Table 20: Latin America Glaucoma Treatment Market Size (US$ Mn) Forecast, by Sales Channel, 2023-2031
  • Table 21: Middle East & Africa Glaucoma Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023-2031
  • Table 22: Middle East & Africa Glaucoma Treatment Market Size (US$ Mn) Forecast, by Product Type, 2023-2031
  • Table 23: Middle East & Africa Glaucoma Treatment Market Size (US$ Mn) Forecast, by Indication, 2023-2031
  • Table 24: Middle East & Africa Glaucoma Treatment Market Size (US$ Mn) Forecast, by Sales Channel, 2023-2031

List of Figures

  • Figure 01: Global Glaucoma Treatment Market Size (US$ Mn) and Distribution (%), by Region, 2023 and 2031
  • Figure 02: Global Glaucoma Treatment Market Revenue (US$ Mn), by Product Type, 2022
  • Figure 03: Global Glaucoma Treatment Market Value Share, by Product Type, 2022
  • Figure 04: Global Glaucoma Treatment Market Revenue (US$ Mn), by Indication, 2022
  • Figure 05: Global Glaucoma Treatment Market Value Share, by Indication, 2022
  • Figure 06: Global Glaucoma Treatment Market Revenue (US$ Mn), by Sales Channel, 2022
  • Figure 07: Global Glaucoma Treatment Market Value Share, by Sales Channel, 2022
  • Figure 08: Global Glaucoma Treatment Market Value Share, by Region, 2022
  • Figure 09: Global Glaucoma Treatment Market Value (US$ Mn) Forecast, 2023-2031
  • Figure 10: Global Glaucoma Treatment Market Value Share Analysis, by Product Type, 2023 and 2031
  • Figure 11: Global Glaucoma Treatment Market Attractiveness Analysis, by Product Type, 2023-2031
  • Figure 12: Global Glaucoma Treatment Market Value Share Analysis, by Indication, 2023 and 2031
  • Figure 13: Global Glaucoma Treatment Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 14: Global Glaucoma Treatment Market Value Share Analysis, by Sales Channel, 2023 and 2031
  • Figure 15: Global Glaucoma Treatment Market Attractiveness Analysis, by Sales Channel, 2023-2031
  • Figure 16: Global Glaucoma Treatment Market Value Share Analysis, by Region, 2023 and 2031
  • Figure 17: Global Glaucoma Treatment Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 18: North America Glaucoma Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023-2031
  • Figure 19: North America Glaucoma Treatment Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 20: North America Glaucoma Treatment Market Value Share Analysis, by Country, 2023 and 2031
  • Figure 21: North America Glaucoma Treatment Market Value Share Analysis, by Product Type, 2023 and 2031
  • Figure 22: North America Glaucoma Treatment Market Value Share Analysis, by Indication, 2023 and 2031
  • Figure 23: North America Glaucoma Treatment Market Value Share Analysis, by Sales Channel, 2023 and 2031
  • Figure 24: North America Glaucoma Treatment Market Attractiveness Analysis, by Product Type, 2023-2031
  • Figure 25: North America Glaucoma Treatment Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 26:North America Glaucoma Treatment Market Attractiveness Analysis, by Sales Channel, 2023-2031
  • Figure 27: Europe Glaucoma Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023-2031
  • Figure 28: Europe Glaucoma Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 29: Europe Glaucoma Treatment Market Value Share Analysis, by Country/Sub-region, 2023 and 2031
  • Figure 30: Europe Glaucoma Treatment Market Value Share Analysis, by Product Type, 2023 and 2031
  • Figure 31: Europe Glaucoma Treatment Market Value Share Analysis, by Indication, 2023 and 2031
  • Figure 32: Europe Glaucoma Treatment Market Value Share Analysis, by Sales Channel, 2023 and 2031
  • Figure 33: Europe Glaucoma Treatment Market Attractiveness Analysis, by Product Type, 2023-2031
  • Figure 34: Europe Glaucoma Treatment Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 35: Europe Glaucoma Treatment Market Attractiveness Analysis, by Sales Channel, 2023-2031
  • Figure 36: Asia Pacific Glaucoma Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023-2031
  • Figure 37: Asia Pacific Glaucoma Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 38: Asia Pacific Glaucoma Treatment Market Value Share Analysis, by Country/Sub-region, 2023 and 2031
  • Figure 39: Asia Pacific Glaucoma Treatment Market Value Share Analysis, by Product Type, 2023 and 2031
  • Figure 40: Asia Pacific Glaucoma Treatment Market Value Share Analysis, by Indication, 2023 and 2031
  • Figure 41: Asia Pacific Glaucoma Treatment Market Value Share Analysis, by Sales Channel, 2023 and 2031
  • Figure 42: Asia Pacific Glaucoma Treatment Market Attractiveness Analysis, by Product Type, 2023-2031
  • Figure 43: Asia Pacific Glaucoma Treatment Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 44: Asia Pacific Glaucoma Treatment Market Attractiveness Analysis, by Sales Channel, 2023-2031
  • Figure 45: Latin America Glaucoma Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023-2031
  • Figure 46: Latin America Glaucoma Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 47: Latin America Glaucoma Treatment Market Value Share Analysis, by Country/Sub-region, 2023 and 2031
  • Figure 48: Latin America Glaucoma Treatment Market Value Share Analysis, by Product Type, 2023 and 2031
  • Figure 49: Latin America Glaucoma Treatment Market Value Share Analysis, by Indication, 2023 and 2031
  • Figure 50: Latin America Glaucoma Treatment Market Value Share Analysis, by Sales Channel, 2023 and 2031
  • Figure 51: Latin America Glaucoma Treatment Market Attractiveness Analysis, by Product Type, 2023-2031
  • Figure 52: Latin America Glaucoma Treatment Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 53: Latin America Glaucoma Treatment Market Attractiveness Analysis, by Sales Channel, 2023-2031
  • Figure 54: Middle East & Africa Glaucoma Treatment Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2023-2031
  • Figure 55: Middle East & Africa Glaucoma Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 56: Middle East & Africa Glaucoma Treatment Market Value Share Analysis, by Country/Sub-region, 2023 and 2031
  • Figure 57: Middle East & Africa Glaucoma Treatment Market Value Share Analysis, by Product Type, 2023 and 2031
  • Figure 58: Middle East & Africa Glaucoma Treatment Market Value Share Analysis, by Indication, 2023 and 2031
  • Figure 59: Middle East & Africa Glaucoma Treatment Market Value Share Analysis, by Sales Channel, 2023 and 2031
  • Figure 60: Middle East & Africa Glaucoma Treatment Market Attractiveness Analysis, by Product Type, 2023-2031
  • Figure 61: Middle East & Africa Glaucoma Treatment Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 62: Middle East & Africa Glaucoma Treatment Market Attractiveness Analysis, by Sales Channel, 2023-2031
目次
Product Code: TMRGL16451

Glaucoma Treatment Market - Scope of Report

TMR's report on the global glaucoma treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global glaucoma treatment market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global glaucoma treatment market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the glaucoma treatment market.

Market Snapshot
Market Value in 2023US$ 6.3 Bn
Market Value in 2031US$ 9.1 Bn
CAGR4.3%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global glaucoma treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global glaucoma treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global glaucoma treatment market.

The report delves into the competitive landscape of the global glaucoma treatment market. Key players operating in the global glaucoma treatment market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global glaucoma treatment market profiled in this report.

Key Questions Answered in Global glaucoma treatment Market Report:

  • What is the sales/revenue generated by glaucoma treatment across all regions during the forecast period?
  • What are the opportunities in the global glaucoma treatment market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Glaucoma Treatment Market - Research Objectives and Research Approach

The comprehensive report on the global glaucoma treatment market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global glaucoma treatment market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global glaucoma treatment market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Glaucoma Treatment Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Glaucoma Treatment Market Analysis and Forecast, 2023-2031

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Glaucoma Treatment Market Analysis and Forecast, by Product Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Product Type, 2023-2031
    • 6.3.1. Prostaglandin Analogs (PGAs)
    • 6.3.2. Alpha Agonist
    • 6.3.3. Beta Blockers
    • 6.3.4. Cholinergic
    • 6.3.5. Carbonic Anhydrase Inhibitors
    • 6.3.6. Combined Medications
  • 6.4. Market Attractiveness Analysis, by Product Type

7. Global Glaucoma Treatment Market Analysis and Forecast, by Indication

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Indication, 2023-2031
    • 7.3.1. Angle Closure Glaucoma (ACG)
    • 7.3.2. Open Angle Glaucoma (OAG)
    • 7.3.3. Secondary Glaucoma
    • 7.3.4. Congenital Glaucoma
    • 7.3.5. Other Indications
  • 7.4. Market Attractiveness Analysis, by Indication

8. Global Glaucoma Treatment Market Analysis and Forecast, by Sales Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Sales Channel, 2023-2031
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Online Sales
  • 8.4. Market Attractiveness Analysis, by Sales Channel

9. Global Glaucoma Treatment Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2023-2031
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Glaucoma Treatment Market Analysis and Forecast

  • 10.1. Introduction
  • 10.2. Key Findings
  • 10.3. Market Value Forecast, by Product Type, 2023-2031
    • 10.3.1. Prostaglandin Analogs (PGAs)
    • 10.3.2. Alpha Agonist
    • 10.3.3. Beta Blockers
    • 10.3.4. Cholinergic
    • 10.3.5. Carbonic Anhydrase Inhibitors
    • 10.3.6. Combined Medications
  • 10.4. Market Value Forecast, by Indication, 2023-2031
    • 10.4.1. Angle Closure Glaucoma (ACG)
    • 10.4.2. Open Angle Glaucoma (OAG)
    • 10.4.3. Secondary Glaucoma
    • 10.4.4. Congenital Glaucoma
    • 10.4.5. Other Indications
  • 10.5. Market Value Forecast, by Sales Channel, 2023-2031
    • 10.5.1. Hospital Pharmacies
    • 10.5.2. Retail Pharmacies
    • 10.5.3. Online Sales
  • 10.6. Market Value Forecast, by Country, 2023-2031
    • 10.6.1. U.S.
    • 10.6.2. Canada
  • 10.7. Market Attractiveness Analysis
    • 10.7.1. By Product Type
    • 10.7.2. By Indication
    • 10.7.3. By Sales Channel
    • 10.7.4. By Country

11. Europe Glaucoma Treatment Market Analysis and Forecast

  • 11.1. Introduction
  • 11.2. Key Findings
  • 11.3. Market Value Forecast, by Product Type, 2023-2031
    • 11.3.1. Prostaglandin Analogs (PGAs)
    • 11.3.2. Alpha Agonist
    • 11.3.3. Beta Blockers
    • 11.3.4. Cholinergic
    • 11.3.5. Carbonic Anhydrase Inhibitors
    • 11.3.6. Combined Medications
  • 11.4. Market Value Forecast, by Indication, 2023-2031
    • 11.4.1. Angle Closure Glaucoma (ACG)
    • 11.4.2. Open Angle Glaucoma (OAG)
    • 11.4.3. Secondary Glaucoma
    • 11.4.4. Congenital Glaucoma
    • 11.4.5. Other Indications
  • 11.5. Market Value Forecast, by Sales Channel, 2023-2031
    • 11.5.1. Hospital Pharmacies
    • 11.5.2. Retail Pharmacies
    • 11.5.3. Online Sales
  • 11.6. Market Value Forecast, by Country/Sub-region, 2023-2031
    • 11.6.1. Germany
    • 11.6.2. U.K.
    • 11.6.3. France
    • 11.6.4. Italy
    • 11.6.5. Spain
    • 11.6.6. Rest of Europe
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Product Type
    • 11.7.2. By Indication
    • 11.7.3. By Sales Channel
    • 11.7.4. By Country/Sub-region

12. Asia Pacific Glaucoma Treatment Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Key Findings
  • 12.3. Market Value Forecast, by Product Type, 2023-2031
    • 12.3.1. Prostaglandin Analogs (PGAs)
    • 12.3.2. Alpha Agonist
    • 12.3.3. Beta Blockers
    • 12.3.4. Cholinergic
    • 12.3.5. Carbonic Anhydrase Inhibitors
    • 12.3.6. Combined Medications
  • 12.4. Market Value Forecast, by Indication, 2023-2031
    • 12.4.1. Angle Closure Glaucoma (ACG)
    • 12.4.2. Open Angle Glaucoma (OAG)
    • 12.4.3. Secondary Glaucoma
    • 12.4.4. Congenital Glaucoma
    • 12.4.5. Other Indications
  • 12.5. Market Value Forecast, by Sales Channel, 2023-2031
    • 12.5.1. Hospital Pharmacies
    • 12.5.2. Retail Pharmacies
    • 12.5.3. Online Sales
  • 12.6. Market Value Forecast, by Country/Sub-region, 2023-2031
    • 12.6.1. China
    • 12.6.2. Japan
    • 12.6.3. India
    • 12.6.4. Australia & New Zealand
    • 12.6.5. Rest of Asia Pacific
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Product Type
    • 12.7.2. By Indication
    • 12.7.3. By Sales Channel
    • 12.7.4. By Country/Sub-region

13. Latin America Glaucoma Treatment Market Analysis and Forecast

  • 13.1. Introduction
  • 13.2. Key Findings
  • 13.3. Market Value Forecast, by Product Type, 2023-2031
    • 13.3.1. Prostaglandin Analogs (PGAs)
    • 13.3.2. Alpha Agonist
    • 13.3.3. Beta Blockers
    • 13.3.4. Cholinergic
    • 13.3.5. Carbonic Anhydrase Inhibitors
    • 13.3.6. Combined Medications
  • 13.4. Market Value Forecast, by Indication, 2023-2031
    • 13.4.1. Angle Closure Glaucoma (ACG)
    • 13.4.2. Open Angle Glaucoma (OAG)
    • 13.4.3. Secondary Glaucoma
    • 13.4.4. Congenital Glaucoma
    • 13.4.5. Other Indications
  • 13.5. Market Value Forecast, by Sales Channel, 2023-2031
    • 13.5.1. Hospital Pharmacies
    • 13.5.2. Retail Pharmacies
    • 13.5.3. Online Sales
  • 13.6. Market Value Forecast, by Country/Sub-region, 2023-2031
    • 13.6.1. Brazil
    • 13.6.2. Mexico
    • 13.6.3. Rest of Latin America
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Product Type
    • 13.7.2. By Indication
    • 13.7.3. By Sales Channel
    • 13.7.4. By Country/Sub-region

14. Middle East & Africa Glaucoma Treatment Market Analysis and Forecast

  • 14.1. Introduction
  • 14.2. Key Findings
  • 14.3. Market Value Forecast, by Product Type, 2023-2031
    • 14.3.1. Prostaglandin Analogs (PGAs)
    • 14.3.2. Alpha Agonist
    • 14.3.3. Beta Blockers
    • 14.3.4. Cholinergic
    • 14.3.5. Carbonic Anhydrase Inhibitors
    • 14.3.6. Combined Medications
  • 14.4. Market Value Forecast, by Indication, 2023-2031
    • 14.4.1. Angle Closure Glaucoma (ACG)
    • 14.4.2. Open Angle Glaucoma (OAG)
    • 14.4.3. Secondary Glaucoma
    • 14.4.4. Congenital Glaucoma
    • 14.4.5. Other Indications
  • 14.5. Market Value Forecast, by Sales Channel, 2023-2031
    • 14.5.1. Hospital Pharmacies
    • 14.5.2. Retail Pharmacies
    • 14.5.3. Online Sales
  • 14.6. Market Value Forecast, by Country/Sub-region, 2023-2031
    • 14.6.1. GCC Countries
    • 14.6.2. South Africa
    • 14.6.3. Rest of Middle East & Africa
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Product Type
    • 14.7.2. By Indication
    • 14.7.3. By Sales Channel
    • 14.7.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
  • 15.2. Market Share Analysis, by Company (2022)
  • 15.3. Company Profiles
    • 15.3.1. Novartis AG
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Product Portfolio
      • 15.3.1.3. SWOT Analysis
      • 15.3.1.4. Financial Overview
      • 15.3.1.5. Strategic Overview
    • 15.3.2. Pfizer, Inc.
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Product Portfolio
      • 15.3.2.3. SWOT Analysis
      • 15.3.2.4. Financial Overview
      • 15.3.2.5. Strategic Overview
    • 15.3.3. Merck & Co., Inc.
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Product Portfolio
      • 15.3.3.3. SWOT Analysis
      • 15.3.3.4. Financial Overview
      • 15.3.3.5. Strategic Overview
    • 15.3.4. Bausch & Lomb Inc.
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Product Portfolio
      • 15.3.4.3. SWOT Analysis
      • 15.3.4.4. Financial Overview
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Allergan Plc
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Product Portfolio
      • 15.3.5.3. SWOT Analysis
      • 15.3.5.4. Financial Overview
      • 15.3.5.5. Strategic Overview
    • 15.3.6. Perrigo Plc
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Product Portfolio
      • 15.3.6.3. SWOT Analysis
      • 15.3.6.4. Financial Overview
      • 15.3.6.5. Strategic Overview
    • 15.3.7. Teva Pharmaceutical Industries Ltd.
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Product Portfolio
      • 15.3.7.3. SWOT Analysis
      • 15.3.7.4. Financial Overview
      • 15.3.7.5. Strategic Overview
    • 15.3.8. Akorn, Inc.
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Product Portfolio
      • 15.3.8.3. SWOT Analysis
      • 15.3.8.4. Financial Overview
      • 15.3.8.5. Strategic Overview
    • 15.3.9. Mobius Therapeutics, LLC
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Product Portfolio
      • 15.3.9.3. SWOT Analysis
      • 15.3.9.4. Financial Overview
      • 15.3.9.5. Strategic Overview